Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy.
Armstrong
P C J
PC
Dhanji
A-R A
AR
Tucker
A T
AT
Mitchell
J A
JA
Warner
T D
TD
D000293:Adolescent; D000328:Adult; D001241:Aspirin / Q000008:administration & dosage; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D000077144:Clopidogrel; D015536:Down-Regulation; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2 / Q000097:blood; D058925:Receptors, Purinergic P2Y12; D013928:Thromboxane A2 / Q000097:blood*; D013929:Thromboxane B2 / Q000097:blood / Q000652:urine; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D055815:Young Adult
C548576:P2RY12 protein, human; D010975:Platelet Aggregation Inhibitors; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D058925:Receptors, Purinergic P2Y12; D013929:Thromboxane B2; D013928:Thromboxane A2; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin